{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:10:01Z","timestamp":1772489401830,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>Drugs targeting <jats:italic toggle=\"yes\">mu<\/jats:italic> opioid receptors are the mainstay of clinical practice for treating moderate-to-severe pain. While they can offer excellent analgesia, their use can be limited by adverse effects, including constipation, respiratory depression, tolerance, and abuse liability. Multifunctional ligands acting at <jats:italic toggle=\"yes\">mu<\/jats:italic> opioid and nociceptin\/orphanin FQ peptide receptors might provide antinociception with substantially improved adverse-effect profiles. This study explored one of these ligands, OREX-1038 (BU10038), in several assays in rodents and nonhuman primates. Binding and functional studies confirmed OREX-1038 to be a low-efficacy agonist at <jats:italic toggle=\"yes\">mu<\/jats:italic> opioid and nociceptin\/orphanin FQ peptide receptors and an antagonist at <jats:italic toggle=\"yes\">delta<\/jats:italic> and <jats:italic toggle=\"yes\">kappa<\/jats:italic> opioid receptors with selectivity for opioid receptors over other proteins. OREX-1038 had long-acting antinociceptive effects in postsurgical and complete Freund\u2019s adjuvant (CFA)-induced thermal hyperalgesia assays in rats and a warm water tail-withdrawal assay in monkeys. OREX-1038 was active for at least 24 h in each antinociception assay, and its effects in monkeys did not diminish over 22 days of daily administration. This activity was coupled with limited effects on physiological signs (arterial pressure, heart rate, and body temperature) and no evidence of withdrawal after administration of naltrexone or discontinuation of treatment in monkeys receiving OREX-1038 daily. Over a range of doses, OREX-1038 was only transiently self-administered, which diminished rapidly to nonsignificant levels; overall, both OREX-1038 and buprenorphine maintained less responding than remifentanil. These results support the concept of dual <jats:italic toggle=\"yes\">mu<\/jats:italic> and nociceptin\/orphanin FQ peptide receptor partial agonists having improved pharmacological profiles compared with opioids currently used to treat pain.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000684","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T15:28:23Z","timestamp":1660145303000},"page":"377-394","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects"],"prefix":"10.1097","volume":"33","author":[{"given":"Lisa R.","family":"Gerak","sequence":"first","affiliation":[{"name":"Department of Pharmacology, University of Texas Health Science Center at San Antonio"},{"name":"Addiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Maguire","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Texas Health Science Center at San Antonio"},{"name":"Addiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerta","family":"Cami-Kobeci","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology, University of Bath, Bath"},{"name":"Current address: School of Life Sciences, University of Bedfordshire, Luton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith M.","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Traynor","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Husbands","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology, University of Bath, Bath"},{"name":"Centre for Therapeutic Innovation, University of Bath, Bath, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles P.","family":"France","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Texas Health Science Center at San Antonio"},{"name":"Addiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"},{"name":"Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisette","family":"Acevedo","sequence":"additional","affiliation":[{"name":"Orexigen Therapeutics Inc., La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Belli","sequence":"additional","affiliation":[{"name":"Orexigen Therapeutics Inc., La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Flynn","sequence":"additional","affiliation":[{"name":"Orexigen Therapeutics Inc., La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-008-1293-6","article-title":"Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys.","volume":"201","author":"Becker","year":"2008","journal-title":"Psychopharmacology"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0304-3959(95)01441-1","article-title":"Characterization of a rat model of incisional pain.","volume":"64","author":"Brennan","year":"1996","journal-title":"Pain"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/ACO.0000000000000216","article-title":"Emerging targets in treating pain.","volume":"28","author":"Chang","year":"2015","journal-title":"Curr Opin Anaesthesiol"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2018.8826","article-title":"Helping to end addiction over the long-term.","volume":"320","author":"Collins","year":"2018","journal-title":"JAMA"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJMra1508490","article-title":"Nonmedical prescription-opioid use and heroin use.","volume":"374","author":"Compton","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","article-title":"A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.","volume":"113","author":"Ding","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"eaar3483","DOI":"10.1126\/scitranslmed.aar3483","article-title":"A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.","volume":"10","author":"Ding","year":"2018","journal-title":"Sci Transl Med"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/jpet.115.231381","article-title":"Combined treatment with morphine and \u03949-tetrahydrocannabinol in rhesus monkeys: antinociceptive tolerance and withdrawal.","volume":"357","author":"Gerak","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s00213-015-4023-x","article-title":"Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys.","volume":"232","author":"Gerak","year":"2015","journal-title":"Psychopharmacology"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1037\/pha0000234","article-title":"Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys.","volume":"27","author":"Gerak","year":"2019","journal-title":"Exp Clin Psychopharmacology"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/1471-2458-11-770","article-title":"Pain as a global public health priority.","volume":"11","author":"Goldberg","year":"2011","journal-title":"BMC Public Health"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.aan0088","article-title":"Time for nonaddictive relief of pain.","volume":"355","author":"Grosser","year":"2017","journal-title":"Science"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors\u2014improved analgesics with reduced side effects?","volume":"175","author":"G\u00fcnther","year":"2017","journal-title":"Br J Pharmacol"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0304-3959(88)90026-7","article-title":"A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.","volume":"32","author":"Hargreaves","year":"1988","journal-title":"Pain"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/cn4000428","article-title":"Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed mu agonist\/delta antagonist opioid analgesic with reduced tolerance liabilities.","volume":"4","author":"Healy","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel \u00b5-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception.","volume":"175","author":"Hill","year":"2018","journal-title":"Br J Pharmacol"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.121.000524","article-title":"The buprenorphine analogue BU10119 attenuates drug-primed and stress-induced cocaine reinstatement in mice.","volume":"378","author":"Hillhouse","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/cpdd.330","article-title":"Safety, tolerability, and antihypertensive effect of SER100, an opiate receptor-like 1 (ORL-1) partial agonist in patients with isolated systolic hypertension.","volume":"6","author":"Kantola","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"article 52","DOI":"10.3389\/fpsyt.2017.00052","article-title":"In vitro and in vivo profile of PPL-101 and PPL-103: mixed opioid partial agonist analgesics with low abuse potential.","volume":"8","author":"Khroyan","year":"2017","journal-title":"Front Psychiatry"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/j.bja.2018.10.065","article-title":"BU10038 as a safe opioid analgesic with few side-effects after systemic and intrathecal administration in primates.","volume":"122","author":"Kiguchi","year":"2019","journal-title":"Br J Anaesth"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects.","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/jpet.119.261511","article-title":"OREX-1019: a novel treatment of opioid use disorder and relapse prevention.","volume":"372","author":"Maguire","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0091-3057(81)90180-5","article-title":"Buprenorphine self-administration by rhesus monkey.","volume":"15","author":"Mello","year":"1981","journal-title":"Pharmacol Biochem Behav"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics.","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.","volume":"10","author":"Singla","year":"2017","journal-title":"J Pain Res"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuron.2016.09.051","article-title":"Re-energizing the development of pain therapeutics in light of the opioid epidemic.","volume":"92","author":"Skolnick","year":"2016","journal-title":"Neuron"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrd.2017.229","article-title":"Biased signaling: from simple switches to allosteric microprocessors.","volume":"17","author":"Smith","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.aai8636","article-title":"A nontoxic pain killer designed by modeling of pathological receptor conformations.","volume":"355","author":"Spahn","year":"2017","journal-title":"Science"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"222","DOI":"10.59566\/IJBS.2011.7222","article-title":"Comparison of the anti-inflammatory and analgesic effects in rats of diclofenac-sodium, felbinac and indomethacin patches.","volume":"7","author":"Takayuma","year":"2011","journal-title":"Int J Biomed Sci"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0026-895X(25)08634-1","article-title":"Modulation by the mu-opioid agonists of guanosine-5\u2019-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.","volume":"47","author":"Traynor","year":"1995","journal-title":"Mol Pharmacol"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","article-title":"A randomized, Phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain.","volume":"157","author":"Viscusi","year":"2016","journal-title":"Pain"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1358\/dot.2018.54.4.2812620","article-title":"The opioid crisis: a 21st century pain.","volume":"54","author":"Walker","year":"2018","journal-title":"Drugs Today"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1021\/cb400113d","article-title":"An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands.","volume":"8","author":"Yekkirala","year":"2013","journal-title":"ACS Chem Biol"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1073\/pnas.1016277108","article-title":"N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of mu\/kappa-opioid heteromers.","volume":"108","author":"Yekkirala","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/nrd.2017.202","article-title":"Breaking barriers to novel analgesic drug development.","volume":"16","author":"Yekkirala","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:00:16Z","timestamp":1749938416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000684","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,3]]}}}